{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T21:18:43Z","timestamp":1774732723937,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03233-4","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:09:52Z","timestamp":1749269392000},"page":"3774-3794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-VEGFs for Diabetic Macular Oedema: Analysis of Efficacy, Safety, and Cost of More Durable Therapies from a Dutch Societal Perspective"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3871-4239","authenticated-orcid":false,"given":"Sara W.","family":"Quist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen H. J.","family":"Paulissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabella","family":"Lunk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marrit A.","family":"Woudstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Pochopien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Nikodem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catriona","family":"Crossan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sankha","family":"Amarakoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freekje","family":"van Asten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"3233_CR1","unstructured":"DiabetesAtlas. 2022. https:\/\/diabetesatlas.org\/#:~:text=Diabetes%20around%20the%20world%20in%202021%3A,%2D%20and%20middle%2Dincome%20countries. Accessed 2023 Dec 13."},{"key":"3233_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364.","journal-title":"Diabetes Care"},{"key":"3233_CR3","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128:1580\u201391.","journal-title":"Ophthalmology"},{"key":"3233_CR4","unstructured":"VZInfo. Diabetes mellitus | Zorguitgaven. https:\/\/www.vzinfo.nl\/diabetes-mellitus\/zorguitgaven. Accessed 2022 Nov 28."},{"issue":"12","key":"3233_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jval.2023.09.1674","volume":"26","author":"S Quist","year":"2023","unstructured":"Quist S, Paulissen J, Freriks RD. HSD123: environmental impact of aflibercept for the treatment of neovascular age-related macular degeneration and diabetic macular oedema in The Netherlands. Value Health. 2023;26(12):317\u20138.","journal-title":"Value Health"},{"key":"3233_CR6","unstructured":"Duphare C, Desai K, Gupta P, et al. Diabetic Macular Edema. [Updated 2023 May\u00a023]. In: StatPearls. Treasure Island (FL): StatPearls; 2025 Jan. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554384\/."},{"key":"3233_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/dme.14125","volume":"37","author":"OAE Cooper","year":"2020","unstructured":"Cooper OAE, Taylor DJ, Crabb DP, Sim DA, McBain H. Psychological, social and everyday visual impact of diabetic macular oedema and diabetic retinopathy: a systematic review. Diabet Med. 2020;37:924\u201333.","journal-title":"Diabet Med"},{"key":"3233_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/939315","volume":"2014","author":"JR Gonder","year":"2014","unstructured":"Gonder JR, Walker VM, Barbeau M, et al. Costs and quality of life in diabetic macular edema: Canadian burden of diabetic macular edema observational study (C-REALITY). J Ophthalmol. 2014;2014:939315.","journal-title":"J Ophthalmol"},{"key":"3233_CR9","unstructured":"Nederlands Oogheelkundig Gezelschap. Diabetische retinopathie."},{"key":"3233_CR10","unstructured":"Summary of Product Characteristics: Lucentis."},{"issue":"6","key":"3233_CR11","volume":"6","author":"G Virgili","year":"2017","unstructured":"Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6(6):CD007419.","journal-title":"Cochrane Database Syst Rev"},{"key":"3233_CR12","unstructured":"Nederlands Oogheelkundig Gezelschap. Brolucizumab - Standpunt WG Medische Retina. 2020. https:\/\/www.oogheelkunde.org\/richtlijn\/brolucizumab-standpunt-wg-medische-retina-2020. Accessed 2020 Aug 18."},{"key":"3233_CR13","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamaophthalmol.2023.5248","volume":"141","author":"RP Singh","year":"2023","unstructured":"Singh RP, Barakat MR, Ip MS, et al. Efficacy and safety of brolucizumab for diabetic macular edema: the KINGFISHER randomized clinical trial. JAMA Ophthalmol. 2023;141:1152\u201360.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"3233_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al. Faricimab treat-and-extend for diabetic macular edema: 2-year results from the randomized phase\u00a03 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"key":"3233_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, et al. Intravitreal aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase\u00a02\/3 trial. Lancet. 2024;403:1153\u201363.","journal-title":"Lancet"},{"key":"3233_CR16","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","volume":"122","author":"DM Brown","year":"2015","unstructured":"Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122:2044\u201352.","journal-title":"Ophthalmology"},{"key":"3233_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","volume":"260","author":"CC Wykoff","year":"2024","unstructured":"Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE phase\u00a03 studies: 100-week results with brolucizumab in patients with diabetic macular edema. Am J Ophthalmol. 2024;260:70\u201383.","journal-title":"Am J Ophthalmol"},{"key":"3233_CR18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16\u00a0weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase\u00a03 trials. Lancet. 2022;399:741\u201355.","journal-title":"Lancet"},{"key":"3233_CR19","unstructured":"Klinische relevantie & pati\u00ebntrelevantie van een Treat-and-Extend beleid in de oogheelkunde bij macula-aandoeninge. 2022. https:\/\/maculavereniging.nl\/wp-content\/uploads\/2022\/05\/29.04.22-Rapport.TE_.behandelbeleid.bij_.macula.aandoeningen.pdf. Accessed 2024 Jun 14."},{"key":"3233_CR20","doi-asserted-by":"publisher","unstructured":"Pr\u00fcnte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5\u00a0mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. https:\/\/doi.org\/10.1136\/0.1136\/bjophthalmol-2015-307249.","DOI":"10.1136\/0.1136\/bjophthalmol-2015-307249"},{"issue":"1","key":"3233_CR21","doi-asserted-by":"publisher","first-page":"22030","DOI":"10.1038\/s41598-020-78954-3","volume":"10","author":"YC Kim","year":"2020","unstructured":"Kim YC, Shin JP, Pak KY, et al. Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema. Sci Rep. 2020;10(1):22030.","journal-title":"Sci Rep"},{"key":"3233_CR22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","volume":"117","author":"M Michaelides","year":"2010","unstructured":"Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study): 12-month data: report 2. Ophthalmology. 2010;117:1078-1086.e2.","journal-title":"Ophthalmology"},{"key":"3233_CR23","unstructured":"European Medicine Agency. Summary of Product Characteristics beovu. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200213147089\/anx_147089_en.pdf."},{"key":"3233_CR24","unstructured":"Renegeron. Two-year results for aflibercept 8\u00a0mg from pivotal photon trial demonstrate durable vision gains at extended dosing intervals in diabetic macular edema. 2023. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/two-year-results-aflibercept-8-mg-pivotal-photon-trial. Accessed 2023 Dec 13."},{"issue":"1","key":"3233_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","volume":"134","author":"JS Heier","year":"2016","unstructured":"Heier JS, Bressler NM, Avery RL, et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol. 2016;134(1):95\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"3233_CR26","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1007\/s12325-023-02675-y","volume":"40","author":"C Watkins","year":"2023","unstructured":"Watkins C, Paulo T, B\u00fchrer C, Holekamp NM, Bagijn M. Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis. Adv Ther. 2023;40:5204\u201321.","journal-title":"Adv Ther"},{"key":"3233_CR27","unstructured":"Nederlandse Oogheelkundige Vereniging (NOG). Leeftijdsgebonden Maculadegeneratie (LMD). 2023. https:\/\/richtlijnendatabase.nl\/richtlijn\/leeftijdsgebonden_maculadegeneratie_lmd\/startpagina_-_leeftijdsgebonden_maculadegeneratie_lmd.html. Accessed 2023 Aug 29."},{"key":"3233_CR28","unstructured":"Dutch Ministry of public health and healthcare. Wachttijden. https:\/\/www.vzinfo.nl\/wachttijden\/ziekenhuiszorg\/polikliniek. Accessed 2022 Dec 26."},{"key":"3233_CR29","unstructured":"Volksgezondheid en Zorg. Ranglijsten - Aandoeningen op basis van zorguitgaven. https:\/\/www.vzinfo.nl\/ranglijsten\/aandoeningen-op-basis-van-zorguitgaven. Accessed 2022 Dec 26."},{"key":"3233_CR30","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","volume":"127","author":"AR Glassman","year":"2020","unstructured":"Glassman AR, Wells JA, Josic K, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol T extension study). Ophthalmology. 2020;127:1201\u201310.","journal-title":"Ophthalmology"},{"key":"3233_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/15569527.2020.1802741","volume":"39","author":"A Chatzirallis","year":"2020","unstructured":"Chatzirallis A, Theodossiadis P, Droutsas K, Koutsandrea C, Ladas I, Moschos MM. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutan Ocul Toxicol. 2020;39:317\u201322.","journal-title":"Cutan Ocul Toxicol"},{"key":"3233_CR32","volume-title":"Decision modelling for health economic evaluation. Handbooks in health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Handbooks in health economic evaluation. Oxford: OUP; 2006."},{"key":"3233_CR33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","volume":"134","author":"EL Ross","year":"2016","unstructured":"Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;134:888\u201396.","journal-title":"JAMA Ophthalmol"},{"key":"3233_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1001\/jamaophthalmol.2022.6142","volume":"141","author":"DW Hutton","year":"2023","unstructured":"Hutton DW, Glassman AR, Liu D, Sun JK. Cost-effectiveness of aflibercept monotherapy vs bevacizumab first followed by aflibercept if needed for diabetic macular edema. JAMA Ophthalmol. 2023;141:268\u201374.","journal-title":"JAMA Ophthalmol"},{"key":"3233_CR35","first-page":"1","volume-title":"Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg","author":"L Hakkaart-van Roijen","year":"2016","unstructured":"Hakkaart-van Roijen L, van der Linden N, Bouwmans C, Kanters T, Swan TS. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Dutch National Health Care Institute; 2016. p. 1\u201373."},{"key":"3233_CR36","first-page":"20","volume":"2022","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;2022:20.","journal-title":"BMC Med"},{"key":"3233_CR37","unstructured":"NICE. Faricimab for treating wet age-related macular degeneration: Technology appraisal guidance [TA800]. 2023. https:\/\/www.nice.org.uk\/guidance\/ta800. Accessed 2023 Nov 7."},{"key":"3233_CR38","unstructured":"Centraal Bureau voor de Statistiek. StatLine - Levensverwachting; geslacht, leeftijd (per jaar en periode van vijf jaren). 2020."},{"key":"3233_CR39","unstructured":"NICE: ta294. https:\/\/www.nice.org.uk\/guidance\/ta294\/documents\/macular-degeneration-wet-agerelated-aflibercept-1st-line-final-appraisal-determination-document2. Accessed 2023 Dec 13."},{"key":"3233_CR40","unstructured":"National Institute for Health and Care Excellence. TA346: Aflibercept for treating diabetic macular oedema. https:\/\/www.nice.org.uk\/guidance\/TA346; 2015. Accessed 2023 Dec 13."},{"key":"3233_CR41","unstructured":"European Medicines Agency. EPAR Eylea. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf. Accessed 2024 Jan 16."},{"key":"3233_CR42","unstructured":"Dutch Statistics. StatLine - Jaarmutatie consumentenprijsindex; vanaf 1963. https:\/\/www.cbs.nl\/nl-nl\/cijfers\/detail\/70936ned. Accessed 2024 Jun 14."},{"key":"3233_CR43","unstructured":"Nederlands Oogheelkundig Gezelschap. Richtlijn Leeftijdgebonden Maculadegeneratie. 2014. http:\/\/www.oogheelkunde.org\/uploads\/gT\/bQ\/gTbQD1fVmIDfBU4fJVt0jA\/Richtlijn-LMD-GEAUTORISEERDE-VERSIE-270314.pdf. Accessed 2020 May\u00a024."},{"key":"3233_CR44","unstructured":"Nederlandse Zorg Authoriteit (NZA). DBC-Zorgproducten. 2022. https:\/\/www.opendisdata.nl\/msz\/zorgproduct. Accessed 2023 Oct 14."},{"key":"3233_CR45","first-page":"1201","volume":"87","author":"CHC Meads","year":"2003","unstructured":"Meads CHC. What is the cost of blindness? J Ophthalmol. 2003;87:1201\u20134.","journal-title":"J Ophthalmol"},{"issue":"7","key":"3233_CR46","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamaophthalmol.2021.1557","volume":"139","author":"M Parravano","year":"2021","unstructured":"Parravano M, Petri D, Maurutto E, et al. Association between visual impairment and depression in patients attending eye clinics: a meta-analysis. JAMA Ophthalmol. 2021;139(7):753\u201361.","journal-title":"JAMA Ophthalmol"},{"key":"3233_CR47","unstructured":"Behandelrichtlijn: Depressie. https:\/\/richtlijnendatabase.nl\/richtlijn\/depressie\/startpagina_-_depressie.html. Accessed 2024 Feb 27."},{"key":"3233_CR48","unstructured":"Statistics D. Dutch Statistics. https:\/\/www.cbs.nl\/nl-nl\/cijfers\/detail\/37296ned. Accessed 2023 Oct 14."},{"key":"3233_CR49","unstructured":"Health Information and Quality Authorization. Guidelines for the Economic Evaluation of Health Technologies in Ireland. https:\/\/www.hiqa.ie\/sites\/default\/files\/2020-09\/HTA-Economic-Guidelines-2020.pdf. Accessed 2024 May\u00a029."},{"key":"3233_CR50","unstructured":"KCE. Belgian guidelines for economic evaluations and budget impact analyses: second edition. https:\/\/kce.fgov.be\/sites\/default\/files\/2021-11\/KCE_183_economic_evaluations_second_edition_Report_update.pdf. Accessed 2024 May\u00a029."},{"key":"3233_CR51","unstructured":"CATDH. Guidelines for the Economic Evaluation of Health Technologies: Canada. 2017. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/economic_guidelines_worked_example.pdf. Accessed 2024 May\u00a023."},{"key":"3233_CR52","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00417-021-05359-x","volume":"260","author":"SW Quist","year":"2022","unstructured":"Quist SW, de Jong LA, van Asten F, Knoester P, Postma MJ, Freriks RD. Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration. Graefe\u2019s Arch Clin Exp Ophthalmol. 2022;260:1083\u201395.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"3233_CR53","first-page":"75","volume":"143","author":"L Goossens","year":"2008","unstructured":"Goossens L, Knoester P, Rutten-Van MM. Avastin (bevacizumab), Macugen (pegaptanib) en Lucentis (ranibizumab): Vergelijking van medicatiekosten. Pharm Weekbl. 2008;143:75\u20139.","journal-title":"Pharm Weekbl"},{"issue":"6","key":"3233_CR54","doi-asserted-by":"publisher","first-page":"e884","DOI":"10.1111\/aos.14712","volume":"99","author":"FD Verbraak","year":"2021","unstructured":"Verbraak FD, Ponsioen DL, Tigchelaar-Besling OAM, et al. Real-world treatment outcomes of neovascular age-related macular degeneration in the Netherlands. Acta Ophthalmol. 2021;99(6):e884\u201392.","journal-title":"Acta Ophthalmol"},{"key":"3233_CR55","doi-asserted-by":"publisher","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL,\nHampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network.\nAflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a\nComparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123(6):1351\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.022.","DOI":"10.1016\/j.ophtha.2016.02.022"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03233-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03233-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03233-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:15:52Z","timestamp":1757182552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03233-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3233"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03233-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sara Quist and Jeroen Paulissen were employees of Asc Academics during this research, which was funded by Bayer. Jeroen Paulissen is now employed by Daiichi Sankyo Nederland B.V. Izabella Lunk, Joao Carrasco, and Marrit Woudstra were an employee of Bayer during the conduct of this research. Michal Pochopien was an employee of Clever Access the conduct of this research, which was funded by Bayer. Mateusz Nikodem and Catriona Crossan were employees of Putnam during the conduct of this research, which was funded by Bayer. Sankha Amarakoon conducted consultancy work for Bayer, Novartis, Horuspharma, and Roche. Freekje van Asten has no conflict of interest to declare. Maarten Postma has received grants and honoraria from various pharmaceutical companies (unrelated to this work) and holds stocks and advisory roles in PAG BV, Health-Ecore, and Asc Academics (all in Groningen, the Netherlands).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}